National Academy of Medicine

The Cost-Effectiveness of Clinical Sequencing

By David L. Veenstra, P. J. Brooks
February 12, 2015 | Discussion Paper

The use of genome sequencing in the clinic has the potential to greatly improve the quality of care that patients receive. However, it is currently unknown how sequencing will impact the overall cost-effectiveness of medicine. This discussion paper, the fifth of seven individually authored commentaries that explores the evidence needed to support the use of genome sequencing in the clinic, examines the major components of the economic value of clinical sequencing and outlines research and policy needs for understanding the overall cost-effectiveness of next-generation sequencing.



Suggested Citation

Veenstra, D. L. and P. J. Brooks. 2015. The Cost-Effectiveness of Clinical Sequencing. NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC. doi: 10.31478/201502h


Disclaimer: The views expressed in this paper are those of the authors and not necessarily of the authors’ organizations, the National Academy of Medicine (NAM), or the National Academies of Sciences, Engineering, and Medicine (the National Academies). The paper is intended to help inform and stimulate discussion. It is not a report of the NAM or the National Academies. Copyright by the National Academy of Sciences. All rights reserved.